Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy et al. · Advanced Drug Delivery Reviews · 1997 · 11K citations

Development Settings, Pharmaceutical Science, Drug Target +8

Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome

Qui‐Lim Choo, George Kuo, Amy J. Weiner et al. · Science · 1989 · 6.9K citations

Vaccination, Viral Replication, Nanbh Agent +15

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al. · New England Journal of Medicine · 2002 · 6.4K citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Michael P. Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet · 2001 · 6K citations

Hepatology, Hepatitis C, Viral Hepatitis +7

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Marc G. Ghany, Doris B. Strader, David L. Thomas et al. · Hepatology · 2008 · 3K citations · Full text